Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Common Equity (2023 - 2025)

Connect Biopharma Holdings' Common Equity history spans 3 years, with the latest figure at $55.4 million for Q3 2025.

  • For Q3 2025, Common Equity fell 44.99% year-over-year to $55.4 million; the TTM value through Sep 2025 reached $55.4 million, down 44.99%, while the annual FY2024 figure was $92.2 million, 9.19% down from the prior year.
  • Common Equity for Q3 2025 was $55.4 million at Connect Biopharma Holdings, down from $71.3 million in the prior quarter.
  • Across five years, Common Equity topped out at $110.9 million in Q2 2024 and bottomed at $55.4 million in Q3 2025.
  • The 3-year median for Common Equity is $93.0 million (2024), against an average of $88.6 million.
  • The largest annual shift saw Common Equity dropped 9.19% in 2024 before it tumbled 44.99% in 2025.
  • A 3-year view of Common Equity shows it stood at $101.5 million in 2023, then decreased by 9.19% to $92.2 million in 2024, then crashed by 39.92% to $55.4 million in 2025.
  • Per Business Quant, the three most recent readings for CNTB's Common Equity are $55.4 million (Q3 2025), $71.3 million (Q2 2025), and $82.9 million (Q1 2025).